All In Biotech

Drug Trial Radar · NCT07853040

A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.

Conditions

  • Hepatic Insufficiency
  • Liver Diseases

Interventions

  • INCB161734Drug

    single dose administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK for plasma INCB161734: CmaxTime frame: Up to approximately 1.5 months
  2. PK for plasma INCB161734: AUClastTime frame: Up to approximately 1.5 months
  3. PK for plasma INCB161734: AUCinfTime frame: Up to approximately 1.5 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Clinical Trials - the Institute For Liver Health

    Chandler, Arizona · Recruiting

  • Orlando Clinical Research Center

    Orlando, Florida · Recruiting

  • Texas Liver Institute - American Research Corporation

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.